Omnicell (OMCL) Up 27% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Omnicell (OMCL). Shares have added about 27% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Omnicell due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.

How Have Estimates Been Moving Since Then?

It turns out, fresh estimates have trended downward during the past month.

The consensus estimate has shifted -46.67% due to these changes.

VGM Scores

At this time, Omnicell has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Omnicell has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry Player

Omnicell belongs to the Zacks Medical Info Systems industry. Another stock from the same industry, Hims & Hers Health, Inc. (HIMS), has gained 2.4% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025.

Hims & Hers Health reported revenues of $586.01 million in the last reported quarter, representing a year-over-year change of +110.7%. EPS of $0.20 for the same period compares with $0.05 a year ago.

For the current quarter, Hims & Hers Health is expected to post earnings of $0.17 per share, indicating a change of +183.3% from the year-ago quarter. The Zacks Consensus Estimate has changed +15.6% over the last 30 days.

Hims & Hers Health has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research